US 8178543
Bi- and tricyclic fused pyrimidines as tyrosine kinase inhibitors
granted A61PA61P1/18A61P11/00
Quick answer
US patent 8178543 (Bi- and tricyclic fused pyrimidines as tyrosine kinase inhibitors) held by Takeda Pharmaceutical Company Limited expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 2
- CPC classes
- A61P, A61P1/18, A61P11/00, A61P13/08, A61P13/12